Factors in first-time adrenocorticotropic hormone therapy and their influence on spasm control time in infantile spasms: a Cox proportional-hazards regression model analysis
WAN Lin, YANG Guang, ZOU Li-Ping, WANG Jing, SHI Xiu-Yu, REN Wei-Hua, LU Qian
Department of Pediatrics, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100853, China
Abstract：Objective To investigate the factors in first-time adrenocorticotropic hormone (ACTH) therapy and their influence on spasm control time in infants with infantile spasms. Methods A total of 72 infants with infantile spasms who were admitted from January 2008 to October 2013 were enrolled. Their clinical data were collected, and the exposure factors for infantile spasms were selected. A Cox proportional-hazards regression model analysis was performed for these factors to analyze their influence on spasm control time. Results Clarification of the etiology (known or unexplained etiology), frequency of spasms before treatment, and presence or absence of combination therapy (ACTH used alone or in combination with magnesium sulfate) had a significant influence on spasm control time in infants with infantile spasms. The infants with a known etiology had a significantly shorter spasm control time than those with unexplained etiology, and the infants with a low frequency of spasms before treatment and receiving ACTH combined with magnesium sulfate early had a significantly longer spasm control time than their counterparts (P < 0.05). Conclusions For infants with infantile spasms at initial diagnosis, etiology should be clarified, which may helpful for evaluating prognosis. A combination of ACTH and magnesium sulfate should be given as soon as possible, which may improve their prognosis.
WAN Lin,YANG Guang,ZOU Li-Ping et al. Factors in first-time adrenocorticotropic hormone therapy and their influence on spasm control time in infantile spasms: a Cox proportional-hazards regression model analysis[J]. CJCP, 2019, 21(9): 845-850.
Hahn J, Lee H, Kang HC, et al. Clobazam as an adjunctive treatment for infantile spasms[J]. Epilepsy Behav, 2019, 95:161-165.
[2]
Zeka N, Gërguri A, Bejiqi R, et al. Compare of the West syndrome with other syndromes in the epileptic encephalopathy -Kosovo experience[J]. Open Access Maced J Med Sci, 2017, 5(7):925-928.
[3]
Yamanaka G, Morishita N, Morichi S, et al. Serial analysis of multiple serum cytokine responses to adrenocorticotropic hormone therapy in patients with West syndrome[J]. J Child Neurol, 2018, 33(8):528-533.
[4]
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies:position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58(4):512-521.
Wanigasinghe J, Arambepola C, Ranganathan SS, et al. Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin:a 12-month assessment of spasm control in West syndrome[J]. Pediatr Neurol, 2017, 76:14-19.
[7]
Oka M, Kobayashi K, Akiyama T, et al. A study of spike-density on EEG in West syndrome[J]. Brain Dev, 2004, 26(2):105-112.
[8]
Yamada K, Toribe Y, Kimizu T, et al. Predictive value of EEG findings at control of epileptic spasms for seizure relapse in patients with West syndrome[J]. Seizure, 2014, 23(9):703-707.
Armstrong D, Said RR. Outcomes of high-dose steroid therapy for infantile spasms in children with trisomy 21[J]. J Child Neurol, 2019:883073819850650. doi:10.1177/0883073819850650.[Epub ahead of print]
[11]
Alqassas MA, Muthaffar OY, Aljawi AA, et al. Treatment of infantile spasms in Saudi Arabia[J]. Neurosciences (Riyadh), 2018, 23(3):258-261.
[12]
Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update:medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society[J]. Neurology, 2012, 78(24):1974-1980.
[13]
Millichap JG, Millichap JJ. Prediction of infantile spasms recurrence after ACTH therapy[J]. Pediatr Neurol Briefs, 2015, 29(12):93.
Hallak M, Berman RF, Irtenkauf SM, et al. Peripheral magnesium sulfate enters the brain and increases the threshold for hippocampal seizures in rats[J]. Am J Obstet Gynecol, 1992, 167(6):1605-1610.
[16]
Osborn KE, Shytle RD, Frontera AT, et al. Addressing potential role of magnesium dyshomeostasis to improve treatment efficacy for epilepsy:a reexamination of the literature[J]. J Clin Pharmacol, 2016, 56(3):260-265.
[17]
Yary T, Kauhanen J. Dietary intake of magnesium and the risk of epilepsy in middle-aged and older Finnish men:a 22-year follow-up study in a general population[J]. Nutrition, 2019, 58:36-39.
[18]
Tan WW, Chan DWS, Lee JH, et al. Use of magnesium sulfate infusion for the management of febrile illness-related epilepsy syndrome:a case series[J]. Child Neurol Open, 2015, 2(1):2329048X14550067.
[19]
Wanigasinghe J, Arambepola C, Sri Ranganathan S, et al. Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin on immediate and continued spasm control in West syndrome[J]. Pediatr Neurol, 2015, 53(3):193-199.
[20]
Ashmawi A, Hosny H, Abdelalim A, et al. The long-term prognosis of newly diagnosed epilepsy in Egypt:a retrospective cohort study from an epilepsy center in Greater Cairo[J]. Seizure, 2016, 41:86-95.
[21]
Salar S, Moshé SL, Galanopoulou AS. Metabolic etiologies in West syndrome[J]. Epilepsia Open, 2018, 3(2):134-166.
[22]
Yang G, Zou LP, Wang J, et al. Neonatal hypoglycemic brain injury is a cause of infantile spasms[J]. Exp Ther Med, 2016, 11(5):2066-2070.
